This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): XL820
Description: XL820 is a SpectrumSelective Kinase Inhibitor (SSKITM) that simultaneously inhibits the receptortyrosine kinases (RTKs) VEGF, KIT and PDGF all of which are clinicallyvalidated targets implicated in a variety of human cancers.
Deal Structure: GlaxoSmithKline and Exelixis have a partnership focused on the collaboration in 12 programs (XL784, XL647, XL999, XL880, XL184, XL820, XL844, XL281, XL418, XL228 and two earlier stage oncology programs). GlaxoSmithKline has the right to select from these programs up to two compounds at proof-of-concept (completion of Phase IIa clinical trial) or three compounds if GlaxoSmithKline extends the collaboration.
In June 2008, Exelixis announced that the company and GlaxoSmithKline will bring their collaboration to a conclusion on October 27, 2008.
In October 2008, Exelixis announced that GlaxoSmithKline decided not to exercise its option to license XL184, XL281, XL228, XL820, and XL844.
Pink Sheet Weekly Trademark Review Jan. 31, 2017
Pink Sheet Weekly Trademark Review Nov. 1, 2016
Additional information available to subscribers only: